Amneal Pharmaceuticals (AMRX)
(Delayed Data from NSDQ)
$8.38 USD
+0.33 (4.10%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $8.38 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Balance Sheet
Fiscal Year End for AMNEAL PHARMACEUTICALS, INC falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 99 | 35 | 257 | 347 | 153 |
Receivables | 615 | 742 | 664 | 640 | 606 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 581 | 531 | 489 | 491 | 381 |
Other Current Assets | 83 | 104 | 110 | 73 | 70 |
Total Current Assets | 1,378 | 1,412 | 1,520 | 1,552 | 1,210 |
Net Property & Equipment | 448 | 470 | 514 | 478 | 478 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 1,489 | 1,695 | 1,760 | 1,827 | 1,802 |
Deposits & Other Assets | 56 | 103 | 21 | 32 | 44 |
Total Assets | 3,473 | 3,799 | 3,940 | 4,006 | 3,666 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 1 | 0 |
Accounts Payable | 535 | 538 | 583 | 614 | 507 |
Current Portion Long-Term Debt | 213 | 90 | 31 | 44 | 21 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 84 | 110 | 48 | 8 | 6 |
Total Current Liabilities | 847 | 753 | 677 | 677 | 550 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 2,427 | 2,632 | 2,718 | 2,772 | 2,609 |
Non-Current Capital Leases | 0 | 0 | 0 | 60 | 61 |
Other Non-Current Liabilities | 42 | 97 | 49 | 87 | 40 |
Minority Interest (Liabilities) | 41 | 25 | 17 | 12 | 0 |
Total Liabilities | 3,453 | 3,615 | 3,573 | 3,661 | 3,319 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 3 | 3 | 3 | 3 | 3 |
Capital Surplus | 539 | 692 | 658 | 628 | 607 |
Retained Earnings | -490 | -406 | -276 | -287 | -378 |
Other Equity | -32 | -105 | -18 | 0 | 115 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 20 | 184 | 367 | 345 | 347 |
Total Liabilities & Shareholder's Equity | 3,473 | 3,799 | 3,940 | 4,006 | 3,666 |
Total Common Equity | 20 | 184 | 367 | 345 | 347 |
Shares Outstanding | 306.50 | 303.60 | 301.50 | 299.70 | 299.10 |
Book Value Per Share | 0.07 | 0.61 | 1.22 | 1.15 | 1.16 |
Fiscal Year End for AMNEAL PHARMACEUTICALS, INC falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 50 | 52 | 99 | 96 | 115 |
Receivables | 779 | 670 | 615 | 693 | 675 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 576 | 571 | 581 | 576 | 551 |
Other Current Assets | 82 | 87 | 83 | 91 | 82 |
Total Current Assets | 1,485 | 1,380 | 1,378 | 1,456 | 1,422 |
Net Property & Equipment | 425 | 440 | 448 | 452 | 459 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 1,418 | 1,458 | 1,489 | 1,581 | 1,615 |
Deposits & Other Assets | 77 | 74 | 56 | 89 | 93 |
Total Assets | 3,510 | 3,456 | 3,473 | 3,687 | 3,701 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 619 | 559 | 535 | 558 | 513 |
Current Portion Long-Term Debt | 436 | 213 | 213 | 107 | 150 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 3 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 44 | 47 | 84 | 80 | 98 |
Total Current Liabilities | 1,114 | 834 | 847 | 761 | 777 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 2,178 | 2,420 | 2,427 | 2,583 | 2,590 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 126 | 42 | 53 | 48 | |
Minority Interest (Liabilities) | 53 | 47 | 41 | 37 | 32 |
Total Liabilities | 3,567 | 3,520 | 3,453 | 3,533 | 3,550 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 3 | 3 | 3 | 3 | 3 |
Capital Surplus | 546 | 539 | 539 | 715 | 708 |
Retained Earnings | -576 | -582 | -490 | -392 | -401 |
Other Equity | -30 | -24 | -32 | -173 | -159 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -57 | -64 | 20 | 154 | 151 |
Total Liabilities & Shareholder's Equity | 3,510 | 3,456 | 3,473 | 3,687 | 3,701 |
Total Common Equity | -57 | -64 | 20 | 154 | 151 |
Shares Outstanding | 309.50 | 308.60 | 306.50 | 306.40 | 306.10 |
Book Value Per Share | -0.19 | -0.21 | 0.07 | 0.50 | 0.49 |